The Cigna Group (CI)
Cigna: I'm Loading Up On This Dividend Growth Stock Now
Cigna's strong fundamentals, including consistent revenue and EPS growth, a solid balance sheet, and undervalued stock price, support a buy rating. The company's Q3 results showed a 29.9% revenue increase and a 10.9% rise in non-GAAP EPS, driven by customer growth and price hikes. Cigna's dividend yield and growth potential are robust, with a low payout ratio and projected double-digit annual EPS growth supporting future dividend increases.
J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports
Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.
Here's Why Cigna (CI) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna's stock leads selloff among drug middlemen on breakup fears — but this analyst says it's not a real risk
One influential healthcare analyst says the chances of such a bill passing are less than 5%.
Health care stocks fall as lawmakers, patients push for changes to their business models
Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.
Here's Why Retaining Cigna Stock is a Smart Move for Investors Now
CI is well-poised for growth on the back of strong contributions from the Evernorth and Cigna Healthcare units. A strong financial position enables it to undertake business investments.
Here's Why Cigna (CI) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips
CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.
3-Stock Lunch: Cigna, Coinbase, & Draft Kings
Victoria Greene, G Squared Private Wealth CIO, joins CNBC's 'Power Lunch' to discuss three stocks: Cigna, Coinbase, and Draft Kings.
Why Cigna Deal With Humana Made Little Sense To Begin With
The Cigna Group confirmed “it is not pursuing a combination with Humana.”
Cigna rallies after Humana mega-merger called off
US health insurer Cigna has made the appropriate decision to ditch plans to merge with rival Humana (NYSE:HUM), if today's market reaction is anything to go by. Rumours of the merger, which would have created a $140 billion insurance behemoth, began circulating last December, but doubts over the deal quickly followed.
